BioRestorative Therapies Reports Promising Advances in Stem Cell Treatments and Commercial Ventures
TL;DR
BioRestorative's promising diabetes and obesity treatment program could capitalize on a $100 billion market for obesity drugs by 2030.
BioRestorative's patented stem cell therapy aims to treat chronic lumbar disc disease and is expanding its preclinical program for ThermoStem®.
BioRestorative's potential diabetes and obesity treatment could improve the lives of millions and reduce healthcare costs for those suffering from these conditions.
BioRestorative's research and clinical trials are paving the way for groundbreaking stem cell therapies to address prevalent health issues like diabetes and obesity.
Found this article helpful?
Share it with your network and spread the knowledge!
BioRestorative Therapies (NASDAQ: BRTX), a clinical-stage biotechnology company, has made significant strides in its stem cell therapy programs, according to its second quarter 2024 business update. The company is focusing on treating chronic lumbar disc disease and metabolic disorders like diabetes and obesity.
Preliminary clinical data from BioRestorative's Disc/Spine Program indicated meaningful signals without notable safety markers in patients treated with BRTX-100. The company has also tripled its monthly trial capacity and aims to complete patient enrollment in its phase 2 study by the end of 2024.
BioRestorative is also laying the groundwork for the commercialization of its BioCosmeceuticals business. An agreement to supply cell-based biologic serum to Cartessa Aesthetics, LLC is expected to generate significant revenue this year.
The company's June 30, 2024, Form 10-Q revealed a 19% improvement in year-over-year operations, with net loss narrowed to $2.5 million compared to $3.1 million in the prior period. BioRestorative's balance sheet showed $14.7 million on hand as of the end of June.
BioRestorative's ThermoStem platform, currently in preclinical testing, aims to treat obesity and metabolic disorders by using stem cells to generate body fat that regulates metabolic homeostasis. This is significant given that nearly 42% of U.S. adults suffer from obesity, with severe obesity affecting over 9%.
Research from Harvard University and George Washington University found that adults with obesity spend $1,861 more annually on medical costs than those without obesity. Severe obesity increases this extra cost to $3,097. The global market for obesity drugs could reach $100 billion by 2030, according to Goldman Sachs, and obesity contributes to up to half of new diabetes cases annually in the U.S.
The global diabetes drug market is projected to reach about $132 billion by 2034, presenting a significant opportunity for BioRestorative's ThermoStem platform. The platform could potentially be used in conjunction with existing drugs like Novo Nordisk's Ozempic or Eli Lilly's Mounjaro.
BioRestorative has also received its fifth Japanese patent for the ThermoStem technology platform, and is in discussions with a regenerative medicine company about licensing the technology. These developments, along with the Cartessa agreement, position the company for potential rapid growth.
Curated from News Direct
